Adjuvant gemcitabine after resection of pancreatic cancer without significant difference in overall survival: a retrospective cohort study.

OS with and without adjuvant chemotherapy with gemcitabine was comparable to the results of those RCTs which serve as the basis of guideline recommendations. However, the analyzed patient cohort did not profit significantly from the adjuvant treatment.